HR Execs on the Move

Macrocure

www.macrocure.com

 
Macrocure Ltd. is a clinical-stage biopharmaceutical company focused on developing a novel therapeutic platform to address chronic and hard-to-heal wounds, such as diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). Our novel approach is to treat and close chronic and other hard-to-heal wounds by injecting the human body`s own wound healing and regenerative components directly into the wound itself.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.macrocure.com
  • Radnor Financial Center, Suite F200 150 North Radnor Road
    Radnor, PA USA 19087
  • Phone: 201.620.6640

Executives

Name Title Contact Details

Similar Companies

Groupe Parima

Groupe Parima is a Saint-Laurent, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Windgap Medical

Windgap Medical is developing health care products that meet the demands of your lifestyle. Our first product will improve the quality of life for patients living with severe allergies.

CoreRx Pharma

CoreRx, Inc. is an industry leading Contract Development and Manufacturing Organization (CDMO), providing innovative drug formulation development, GMP manufacturing and packaging solutions to global pharmaceutical and bio-pharmaceutical partners. From its state-of-the-art, multi-site campus in Clearwater, Florida and its early product development center of excellence in San Rafael, California, CoreRx delivers value-added solutions to its partners, from clinic to commercial scale and across a range of dosage forms.

Hemagen Diagnostics

Hemagen Diagnostics is a Columbia, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ascentage Pharma

Ascentage Pharma is a globally-focused, clinical-stage biopharmaceutical company developing novel small molecule therapies for cancers, hepatitis B and age-related diseases. Based on breakthrough technology from the University of Michigan, the Company`s expertise is in designing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death, in cancers. Ascentage has built a rich pipeline of six clinical candidates, including a novel, highly potent Bcl-2/Bcl-xL inhibitor, APG-1252, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors.